SuperworthVanda Pharmaceuticals EPS VNDA
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$4.63
- Latest quarter, Q2 FY26
- −$1.04
- Fiscal year 2025
- −$3.73
Vanda Pharmaceuticals' earnings per share was −$4.63 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.04.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.73 | n/a |
| FY2024 | −$0.32 | −740% |
| FY2023 | $0.05 | −58% |
| FY2022 | $0.12 | −79% |
| FY2021 | $0.58 | +35% |
| FY2020 | $0.43 | −80% |
| FY2019 | $2.12 | +351% |
| FY2018 | $0.47 | n/a |
| FY2017 | −$0.34 | n/a |
| FY2016 | −$0.42 | n/a |
| FY2015 | −$0.94 | −413% |
| FY2014 | $0.30 | n/a |
| FY2013 | −$0.68 | n/a |
| FY2012 | −$0.98 | n/a |
| FY2011 | −$0.36 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.04 | n/a | −$4.63 | |
| Q1 FY26 | −$0.82 | n/a | −$4.05 | |
| Q4 FY25 | −$2.39 | n/a | −$3.73 | |
| Q3 FY25 | −$0.38 | n/a | −$1.42 | |
| Q2 FY25 | −$0.46 | n/a | −$1.13 | |
| Q1 FY25 | −$0.50 | n/a | −$0.75 | |
| Q4 FY24 | −$0.08 | n/a | −$0.32 | |
| Q3 FY24 | −$0.09 | n/a | −$0.28 | |
| Q2 FY24 | −$0.08 | −367% | −$0.19 | |
| Q1 FY24 | −$0.07 | −217% | −$0.08 | |
| Q4 FY23 | −$0.04 | −133% | $0.05 | |
| Q3 FY23 | $0.00 | −100% | $0.21 |
Against its peers
Companies in Drug Manufacturers - General nearest Vanda Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| VNDAVanda Pharmaceuticals | −$4.63 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| ABUSArbutus Biopharma | $0.78 | |
| SPROSpero Therapeutics | $0.11 | |
| Peer median | $0.78 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Vanda Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.